Name in SEC filings: Climb Bio, Inc.
| Program | Event | Stage | Stated timing | Filing |
|---|---|---|---|---|
| budoprutug | /data readout | Stage not stated | in the fourth quarter of 2026 | 8-K · |
| budoprutug | Topline/data readout | Stage not stated | in the fourth quarter of 2026 | 8-K · |
| budoprutug | Topline/data readout | Stage not stated | in the fourth quarter of 2026 | 8-K · |
| CLYM116 | Topline/data readout | Phase 1 | in the fourth quarter of 2026 | 8-K · |
| CLYM116 | Topline/data readout | Phase 2 | in the first half of 2027 | 8-K · |
| budoprutug | Topline/data readout | Stage not stated | in 2027 | 8-K · |
| CLYM116 | Other | Phase 3 | in 2027 | 8-K · |
Source: ORION, orionbiotechai.com/company/CLYM, data as of Oct 16, 2026
https://www.orionbiotechai.com/company/CLYM
budoprutug · Topline/data readout · in the fourth quarter of 2026
SEC sources last checked .
○ Quote matched to filing (not yet reviewed by founder) · ✓ Checked by founder.
Topline/data readoutin the fourth quarter of 2026
Stage: Not stated
Public float: Unknown (no public float found in SEC filings).
Anticipate additional data from the 500 mg and 1000 mg cohorts in the fourth quarter of 2026.
SEC timing context:
Presented initial Phase 1b data in previously treated immune thrombocytopenia (ITP) patients at European Hematology Association Congress
8-K · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2026-12)
Topline/data readoutin the fourth quarter of 2026
Stage: Not stated
Public float: Unknown (no public float found in SEC filings).
Enrollment is now ongoing in the second cohort (600 mg) and anticipate initial data, including preliminary B cell and anti-PLA2R data from low dose cohort (200mg at 12-24 weeks), at a medical meeting in the fourth quarter of 2026.
SEC timing context:
PrisMN Phase 2 primary membranous nephropathy (pMN) trial, enrollment ongoing.
8-K · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2026-12)
Topline/data readoutin the fourth quarter of 2026
Stage: Not stated
Public float: Unknown (no public float found in SEC filings).
Anticipate data, including safety and biomarker data from the Global study in the fourth quarter of 2026.
SEC timing context:
First patient dosed in China Phase 1b/2a trial of budoprutug in systemic lupus erythematosus (SLE); Global Phase 1b SLE trial enrollment
8-K · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2026-12)
Topline/data readoutin the fourth quarter of 2026
Stage: Phase 1SEC filing · “Phase 1; Phase 1”
Public float: Unknown (no public float found in SEC filings).
Additional data from the ongoing Phase 1 study and initial reporting of Beijing Mabworks Biotech Co., Ltd. (Mabworks) Phase 1 healthy volunteer study in China to be presented at an upcoming medical meeting in the fourth quarter of 2026
SEC timing context:
The data presented today are from the Company’s ongoing Phase 1 trial of CLYM116.
8-K · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2026-12)
Topline/data readoutin the first half of 2027
Stage: Phase 2SEC filing · “Phase 2”
Public float: Unknown (no public float found in SEC filings).
Initial data from NAVIGATE-2 Phase 2 anticipated in the first half of 2027
SEC timing context:
Phase 2 NAVIGATE-2 trial in IgA nephropathy ongoing; anticipate initial data in H1 2027, Phase 3 study initiation in 2027
8-K · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2027-06)
Topline/data readoutin 2027
Stage: Not stated
Public float: Unknown (no public float found in SEC filings).
Plan to initiate a multiple-dose study of the SC formulation in autoimmune patients; anticipate initial data in 2027.
SEC timing context:
Presented positive topline data for subcutaneous (SC) formulation of budoprutug at Company R&D Spotlight in May 2026.
8-K · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2027-12)
Otherin 2027
Stage: Phase 3SEC filing · “Phase 3”
Public float: Unknown (no public float found in SEC filings).
Initiation of Phase 3 registrational study anticipated in 2027
SEC timing context:
Phase 2 NAVIGATE-2 trial in IgA nephropathy ongoing; anticipate initial data in H1 2027, Phase 3 study initiation in 2027
8-K · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2027-12)
Company periods and sentences are quoted as written. A matching disclosure uses the SEC filing date for the same program and event type. As of .
| Program / event | Stated period and SEC wording | Disclosure in stated period |
|---|---|---|
| CLYM116Clinical results | in the first half of 2027“Initial data from NAVIGATE-2 Phase 2 anticipated in the first half of 2027” Filed · EX-99.1 | Period not started The stated period has not started yet, so there is nothing to compare. |
| CLYM116Clinical results | in the fourth quarter of 2026“Additional data from the ongoing Phase 1 study and initial reporting of Beijing Mabworks Biotech Co., Ltd. (Mabworks) Phase 1 healthy volunteer study in China to be presented at an upcoming medical meeting in the fourth quarter of 2026” Filed · EX-99.1 | Still within period As of Oct 19, 2026 |
| CLYM116Other | in 2027“Initiation of Phase 3 registrational study anticipated in 2027” Filed · EX-99.1 | Period not started The stated period has not started yet, so there is nothing to compare. |
| budoprutugClinical results | in the fourth quarter of 2026“Anticipate additional data from the 500 mg and 1000 mg cohorts in the fourth quarter of 2026.” Filed · EX-99.1 | Still within period As of Oct 19, 2026 |
| budoprutugClinical results | in the fourth quarter of 2026“Enrollment is now ongoing in the second cohort (600 mg) and anticipate initial data, including preliminary B cell and anti-PLA2R data from low dose cohort (200mg at 12-24 weeks), at a medical meeting in the fourth quarter of 2026.” Filed · EX-99.1 | Still within period As of Oct 19, 2026 |
| budoprutugClinical results | in 2027“Plan to initiate a multiple-dose study of the SC formulation in autoimmune patients; anticipate initial data in 2027.” Filed · EX-99.1 | Period not started The stated period has not started yet, so there is nothing to compare. |
| budoprutugClinical results | in the fourth quarter of 2026“Anticipate data, including safety and biomarker data from the Global study in the fourth quarter of 2026.” Filed · EX-99.1 | Still within period As of Oct 19, 2026 |
“Not compared” means ORION has not matched this wording against a complete set of SEC filings for its period. It says nothing either way about whether a matching filing exists. Wording without exact dates is not given calendar dates.
Suggest an SEC timing statement to add for CLYM. You can include the original filing link in your note. The founder reads each request by hand.
Or email ORION.
See CLYM in the calendar · Review labels and methodology